Outcome-centered antiepileptic therapy: Rate, rhythm and relief. Implementing AAN Epilepsy Quality Measures in clinical practice by D'Cruz, O'Neill
Epilepsy & Behavior 53 (2015) 108–111
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /yebehReviewOutcome-centered antiepileptic therapy: Rate, rhythm and relief.
Implementing AAN Epilepsy Quality Measures in clinical practice
O'Neill D'Cruz ⁎
Cyberonics, USA
100 Cyberonics Blvd, Houston, TX 77058, USA⁎ Tel.: +1 919 951 8085; fax: +1 281 853 2708.
E-mail address: oneill_dcruz@yahoo.com.
http://dx.doi.org/10.1016/j.yebeh.2015.09.021
1525-5050/© 2015 The Author. Published by Elsevier Inc.a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 July 2015
Revised 17 September 2015
Accepted 19 September 2015
Available online 3 November 2015
Keywords:
Seizures
Antiepileptic drugs
Vagus nerve stimulation
Quality of life
OutcomesClinicians whomanage patients with epilepsy are expected to assess the relevance of clinical trial results to their
practice, integrate new treatments into the care algorithm, and implement epilepsy quality measures, with the
overall goal of improving patient outcomes. A disease-based clinical framework that helps with choice and com-
binations of interventions facilitates provision of efﬁcient, cost-effective, and high-quality care. This article
addresses the current conceptual framework that informs clinical evaluation of epilepsy, explores gaps between
development of treatment options, quality measures and clinical goals, and proposes an outcome-centered
approach that bridges these gaps with the aim of improving patient and population-level clinical outcomes
in epilepsy.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite modern advances in antiepileptic therapy, the burden of
epilepsy continues to be amajor clinical challenge. The burden of seizures
is compounded by associated neurological comorbidities and adverse ef-
fects of treatment. Moreover, epilepsy is the second highest among neu-
rological disorders in years of potential life lost (YPLL) [1]. Various
groups involved in clinical care and research and development (e.g., clini-
cians, regulators, industry and health policy personnel, payers) address
these challenges within separate frameworks which are appropriate to
their respective enterprise. This article addresses the current conceptual
framework that informs clinical evaluation of epilepsy, explores gaps be-
tween various frameworks, and proposes an outcome-centered clinical
approach that bridges these gaps with the aim of improving patient and
population-level clinical outcomes in epilepsy.
2. Clinical evaluation
Clinical evaluation in patients with epilepsy includes assessment
of frequency, severity and duration of seizures, comorbidities and side
effects of treatment, and adherence to treatment regimens. Epilepsy
quality measures have been recently updated to standardize clinical
assessments [2]. These measures and assessments reﬂect biological
principles (Fig. 1) and help clinicians to formulate and revise treatment
plans. Results are typically assessed by seizure freedom rates andThis is an open access article under tquality-of-life measures. When treatment goals cannot be achieved
with standard treatments, patients may be enrolled in clinical trials.
3. Gaps between trials and clinical goals
The same biological principles used to formulate treatment plans in-
form clinical development of antiepileptic therapies, and results of con-
trolled trials should, in theory, align with clinical effectiveness. Gaps are
created when there is incomplete alignment between different frame-
works for clinical development and practice (Table 1). Development
of treatment options for epilepsy could potentially target any of the
disease domains — seizure frequency, severity, or duration or quality-
of-life effects— that inﬂuence clinical outcomes. However, clinical trials
are designed to assess efﬁcacy of intervention on a prespeciﬁed single
primary endpoint. Due to the well-known and reliable effect of antiep-
ileptic drugs on seizure frequency, all clinical trials for antiepileptic
drugs (AEDs) and devices evaluate effect on intervention on the same
primary endpoint— seizure frequency.
Since clinical trials of adjunctive AED therapy enroll patients who
have persistent seizures despite adequate doses of two or more stan-
dard treatments, these patients typically meet the ILAE deﬁnition of
drug-resistant epilepsy [3]. The possibility of seizure freedom with
another drug in a patient with drug-resistant epilepsy is considerably
lower than that expected with de novo use of AEDs [4,5]. Hence, clinical
trials are typically designed andpowered to assess a fractional reduction
in seizure frequency rather than seizure freedom (endpoint gap be-
tween goals in practice and trials). Based on regulatory guidelines,
a comparator is required to demonstrate beneﬁt, in superiority (US) orhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinical trials is established as superiority to placebo or noninferiority
to standard AEDs (design gap). Unlike clinical practice where sustained
seizure freedom is measured in years, controlled trials last for a matter
of months (duration-of-assessment gap). Moreover, unlike a practice
cohort where clinical effectiveness is desired for all patients started
on an intervention, efﬁcacy in controlled trials is assessed on a narrow
disease spectrum (deﬁned by inclusion and exclusion criteria), and
long-term efﬁcacy is often reported on completer cohorts, rather than
enrolled population. Since retention rates in clinical trials typically
drop over time, whereas clinicians manage all patients over time, this
creates another gap (cohort gap) between trial and practice.
Successful trials using the current approach are the basis of regulato-
ry approval of all new therapies. While randomized trials provide high-
quality evidence, clinical and trial frameworks are not aligned due to
these gaps. Hence, it should not be surprising that there is no apprecia-
ble change in seizure freedom rates despite availability of multiple new
drugs and devices for clinical use [5].
4. Bridging gaps between trials and clinical practice
From a clinical practice perspective, the beneﬁt of novel interven-
tions may be enhanced by demonstrating superiority of a novel inter-
vention to standard-of-care on a prespeciﬁed, clinically relevant,
primary endpoint (e.g., seizure freedom for a seizure frequency end-
point). The primary endpoint can target disease domains beyond sei-
zure frequency — severity, duration, and quality of life — in pivotal
trials, in order to align interventions with clinical goals. Thus, all four
clinical domains present potential opportunities for improvements in
future development of treatment options. Impact on health-economic
and health-care utilization over longer periods can be incorporated
into “real-world” trials designed to demonstrate both clinical- and
cost-effectiveness of novel interventions over standard-of-care.Table 1
Gaps between trials and practice.
Type of gap Trials Practice
Endpoint gap Seizure reduction Seizure remission
Design gap Noninferiority to SOCa Superiority to SOCa
Duration of assessment gap Weeks/months Years
Patient cohort gap Limited spectrum,
completers
Full spectrum, enrolled
Domain gap One clinical domain All clinical domains
a Standard of care.From a clinical trials perspective, the initial challenge is formulating
a generally accepted clinical standard-of-care based on disease charac-
teristics and clinical domains. The next set of challenges includes
developing trial models and development plans that target various
domains, followed by outcome-oriented endpoints (see below). Re-
cent advances in genetics, epilepsy network analysis, and application
of predictive analytics to large datasets provide the means to test
and develop new approaches for subpopulations and disease subsets.
The opportunity is the aim and promise of superior outcomes over
current standard-of-care.
5. Optimizing antiepileptic therapy
We need a treatment approach that deﬁnes, rather than being limit-
ed or deﬁned by, clinical trial endpoints. We need to consider ap-
proaches that combine therapies to further improve outcomes beyond
reduction in seizure frequency.
In patients with persistent seizures, quantity of seizures is an impor-
tant, but not the sole, factor that inﬂuences quality of life. Seizure worry
and depression, side effects of drugs, comorbidities, and lack of ad-
herence are nonfrequency related factors that impact quality-of-life
outcomes [6–8]. A treatment approach that focuses on optimizing
outcomes should target all four disease domains that are routinely
assessed in clinical practice. In neurology, migraine offers an example
of combining prophylactic, symptomatic, and lifestyle interventions to
reduce the burden of disease. A similar disease-based clinical frame-
work approach may be considered in epilepsy.
6. Outcome-centered antiepileptic therapy: a disease-based
clinical framework
In other areas of medicine (notably cardiology), multimodal ap-
proaches that offer unique and complementary beneﬁts are routinely
combined in care algorithms. While neural networks are considerably
more complex than cardiac conduction pathways, there are similarities
in clinical expression that could inform similar treatment approaches
(Table 2). Both epileptic disorders and cardiac rhythm disorders share
common biological factors of genetic predisposition, abnormal organ
substrate, and systemic/environmental triggers that lead to an enduring
predisposition to “arrhythmias”. Interictal electrophysiological abnor-
malities may be present on both the EEG and ECG, with or without acti-
vation procedures, and paroxysmal events in both systems have well-
deﬁned onset, propagation, and recurrence patterns. Comorbidities
contribute to poorer outcomes in both epilepsy and cardiac disease.
Table 2
Treatment approaches— biological basis in cardiology and epilepsy.
Approach Biological basis Cardiac arrhythmia Antiepileptic therapy
Rate-control therapy Manage rate Control ventricular rate Control seizure rate (frequency)
Rhythm-control therapy Detect and prevent propagation and/or
prolongation of abnormal activity
Restore sinus rhythm after onset of arrhythmia Restore EEG to non-ictal patterns after onset of seizure
Relief therapy Reduce disease and treatment burden
(comorbidities, adverse events)
Manage systemic disease, stressors, improve
quality of life
Manage CNS comorbidities and stressors,
improve quality of life
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fully used to improve outcomes in cardiology may be explored to im-
prove outcomes in epilepsy.
Outcome-centered antiepileptic therapy integrates various comple-
mentary approaches — rate, rhythm and relief — to link treatments to
established clinical goals and optimize clinical outcomes (Table 3).
6.1. Rate-control therapy
The ultimate clinical goal of reducing the rate or frequency of seizures
(rate-control therapy) is sustained seizure freedom,without unacceptable
side effects. Seizure freedom is achieved in approximately two-thirds of
patients with epilepsy with antiepileptic drug therapy [5]. Epilepsy sur-
gery offers a median of 62.4% seizure freedom rate in surgically eligible
patients with drug-resistant focal epilepsy [9] and is the preferred rate-
control therapy for these patients. For patientswith drug-resistant epilep-
sywho are not seizure-free (both postsurgical and nonsurgical), diet- and
device-based therapies (e.g., VNS, RNS) offer other options for rate-
control therapy. The combination ofmultimodal rate-control therapies is
one example of optimizing treatment outcomes and is underutilized in
clinical practice despite offering convincing clinical beneﬁt [10,11].
Although necessary, rate-control therapy is insufﬁcient when sei-
zure freedom without unacceptable side effects is clinically infeasible.
In these patients, a substantial portion of the morbidity and mortality
risks is due to the clinical consequences of the other disease domains
and requires other therapies targeted toward these domains. Since
rate-control therapies are emphasized in clinical practice, further details
are omitted here to focus on other therapeutic approaches.
6.2. Rhythm-control therapy
Unlike rate-control therapies which aim to reduce the frequency of
clinical events, rhythm-control approaches are activated at or after
onset of an “arrhythmic” event to reduce severity, duration, and adverse
clinical consequences (e.g., implanted cardioverters-deﬁbrillators). A
considerable amount of epilepsy-related morbidity (falls, fractures,
burns, accidents, etc) is due to the severity of seizures. The clinical
goal of rhythm-control therapy in epilepsy is to limit the propagation
of a seizure across the epileptic network and reduce the associated clin-
ical consequences. These therapies may be classiﬁed as early or late, de-
pending on the interval between onset of a seizure and delivery of
therapy.Table 3
Types and goals of interventions in epilepsy.
Type Goal Examples of intervention
Rate-control Reduce seizure frequency
Time-basis: long-term
Antiepileptic drugs
Surgery
Devices
Diets
Rhythm-control Reduce severity and duration of seizures
Time-basis: acute
Open-loop device systems
Closed-loop device systems
Drugs (e.g., benzodiazepine
Relief Reduce burden of disease on quality of life
Time-basis: ongoing
Treatment side effects man
Lifestyle interventions
Treatment of comorbiditiesEarly rhythm-control therapies are interventions at or following
onset of a seizure. While early rhythm-control therapy in arrhythmias
is standard-of-care in cardiology, we do not have controlled clinical
trials for similar therapies in epilepsy. Hence, clinical use of available
rhythm-control approaches is based on observational clinical data.
In epilepsy, these include device-based open-loop and closed-loop op-
tions. With the use of open-loop magnet mode of VNS therapy, 45% of
patients report clinical beneﬁt on seizure severity, duration, or recovery,
with 28% reporting cessation of seizures [12]. These effect sizes of
rhythm-control therapy on seizure duration and severity are
comparable to those of drugs and device-based rate-control therapies
on seizure frequency. Closed-loop options, such as responsive neuro-
stimulation(RNS) and the AspireSR VNS device, automate rhythm-
control therapy. Investigation and utilization of early rhythm-control
approaches to reduce seizure severity and duration are a clinically rele-
vant opportunity for future antiepileptic therapy development.
Late rhythm-control therapy is a “fail-safe” to manage seizures that
continue despite early rhythm-control approaches. The use of benzodi-
azepines, as rescue therapy for repetitive seizures and for acute inter-
vention of prolonged seizures, represents the most commonly used
late rhythm-control therapy. This reactive approach is intended to
limit morbidity associated with repetitive or prolonged seizures. Treat-
ment of status epilepticus is, in essence, an urgent late rhythm-control
strategy (details of treatment of status epilepticus are beyond the
scope of this article).
Successful rhythm-control approaches would be expected to hinder
the progression of seizures to generalized convulsive seizures or status
epilepticus. The use of appropriate rhythm-control strategies can con-
tribute to better outcomes by alleviating severity andduration of clinical
events aswell as patient/caregiver concerns (i.e., seizureworry) regard-
ing these domains.6.3. Relief therapy
Network effects associated with epilepsy, comorbidities, and side
effects of antiepileptic therapies are a signiﬁcant contributor to poor qual-
ity of life, especially in patients with drug-resistant epilepsy. In these pa-
tients, optimizing outcomes by relieving the burden of these factors
(hence, “relief” therapy) is another clinical challenge and opportunity.
Yet, this opportunity is often overlooked, especiallywhen a treatment ap-
proach is predominantly focused on rate-control therapies.2014 Epilepsy Update Quality Measurement Set
1a (seizure frequency), 2 (disease features), 4 (seizure safety), 7 (referral)
s)
1b (seizure intervention), 4 (seizure safety)
agement 3 (side effect management), 5 (psychiatric comorbidities),
6 (counseling for women with epilepsy)
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can either avoid ormitigate the additional burden associated with factors
that drive network effects. These are summarized as “TLC” below, bor-
rowing a common clinical care acronym (note — interventions may be
similar to those noted earlier; the domain of interest determines the
goal of treatment and impact on outcome). Other aspects of care that re-
duce the nonseizure-related burden can also be considered as relief ther-
apies and, while clinically relevant, are beyond the scope of this article.
6.3.1. T — treatment-associated effects
6.3.1.1. Nonadherence. Nonadherence with AEDs is associated with an
over threefold increase in risk of mortality compared to adherence,
as well as a higher risk of morbidity and health-care utilization [8].
Combining an active (opt-in) modality such as drugs or diets with an
automatic (opt-out) device-modality reduces the risk of treatment
nonadherence and epilepsy-related clinical events as well as health-
care utilization [13].
6.3.1.2. Side effects. Adverse effects of antiepileptic drugs are associated
with poor quality of life in patients with epilepsy [7], and CNS side ef-
fects on balance and sedation are nearly universal to all AEDs. Systemic
effects of AEDs also need to be evaluated and managed, including sys-
temic and organ toxicity and drug–drug interactions. It is standard-of-
care in oncology to combine multimodal approaches to improve treat-
ment response and limit toxicity. Similarly, multimodal approaches
in epilepsy, including early surgical referral and drug–device–diet com-
binations (polytherapy) to reduce CNS side effects and/or treat comor-
bidities, would considerably reduce the treatment burden associated
with multiple drugs (polypharmacy).
6.3.2. L — lifestyle interventions
Sleep disturbances contribute to destabilization of seizure control,
and management of sleep disorders offers opportunities for relief ther-
apy, with effect sizes comparable to those of standard antiepileptic
therapies [14]. Stress reduction and environmentalmodiﬁcations (espe-
cially in reﬂex epilepsies) provide other opportunities for lifestyle inter-
ventions. Excessive alcohol and caffeine consumption and drug abuse
may also contribute to destabilizing seizure control and offer potential
intervention opportunities. Attention to exercise, diet, and social sup-
port are among the generally helpful lifestyle interventions.
6.3.3. C — comorbidities
The prevalence and impact of comorbidities (e.g., migraine, depres-
sion, anxiety) are other contributors to poor quality of life in epilepsy
and offer opportunities to provide additional relief beyond manage-
ment of seizures. Network effects that inﬂuence cognitive and behav-
ioral domains can also be addressed through speciﬁc interventions.
Antiepileptic drugs and devices, which are indicated for management
of some of these comorbidities, allow judicious choices of therapy to
reduce the burden of both disease and interventions [15].
7. Outcome-centered approach: combining rate, rhythm and
relief therapies
When evaluating a patientwith epilepsy, the points to consider in an
outcome-centered approach are the following:
a) Have all disease domains— frequency, severity, duration of seizures,
and quality-of-life effects— been evaluated for impact on outcome?
b) Which combination of the three approaches — rate, rhythm, and
relief — is most appropriate to achieve the desired outcome?
Since the clinical goal is to improve outcomes at all stages of illness,
the proposed outcome-centered approach will lead to different choices
of therapy in individual patients. Of note, this approach is well-aligned
with bedside clinical assessments and quality-of-life indicators andprovides a means of implementing epilepsy quality measures. Applying
it consistently in clinical practice will uncover opportunities to improve
outcomes at both patient and population levels. Using it as a guide for
development of future antiepileptic therapies will lead to novel study
designs, with endpoints that represent a conﬂuence of clinical, regulato-
ry, and health economic goals.
Outcome-centered treatment may be viewed as a form of personal-
ized medicine that integrates clinical knowledge, treatment goals, and
patient preferences. Colleagues in other specialties, notably cardiology
and oncology, use outcome-centered measures, such as quality-of-life
measures, disease-free survival and hospitalization, and mortality
rates to demonstrate superiority to standard-of-care. By developing
and adopting novel outcome-centered interventions and combination
therapies, they have served their patients and profession well and im-
proved population-level outcomes at a pace that far surpasses our cur-
rent approach.
As quality-of-care assessments transition from patient-level to
population-level metrics, it is important to identify gaps between con-
ceptual frameworks used for developing treatments, providing point-
of-service care, and public health goals. Failure to recognize and bridge
these gaps often leads to overutilization of resources without commen-
surate improvements in quality or outcomes. The outcome-centered ap-
proach outlined in this article is grounded in clinical care principles. It
allows clinicians, industry and health policy personnel to identify bar-
riers and build bridges to better solutions— and in turn, a better tomor-
row for our patients, their caregivers, and society.
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